Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

OBJECTIVE: To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn's disease (CD) naïve to immunosuppressants and biologics using a UK public payer persp...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	GUT 2020-04, Vol.69 (4), p.658-664
Hauptverfasser:	Panaccione, Remo, Colombel, Jean-Frederic, Travis, Simon P.L, Bossuyt, Peter, Baert, Filip, Vanasek, Tomas, Danalioglu, Ahmet, Novacek, Gottfried, Armuzzi, Alessandro, Reinisch, Walter, Johnson, Scott, Buessing, Marric, Neimark, Ezequiel, Petersson, Joel, Lee, Wan-Ju, D'Haens, Geert R
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!